Literature DB >> 23299771

A tale of two histiocytic disorders.

Filip Janku1, Javier Munoz, Vivek Subbiah, Razelle Kurzrock.   

Abstract

Mesh：

Year:  2013        PMID： 23299771      PMCID： PMC3556250          DOI： 10.1634/theoncologist.2012-0440

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  31 in total

1.  Response of histiocytoses to imatinib mesylate: fire to ashes.

Authors:  Filip Janku; Hesham M Amin; Dan Yang; Ignacio Garrido-Laguna; Jonathan C Trent; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2010-08-23       Impact factor: 44.544

2.  Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.

Authors:  Achille Aouba; Sophie Georgin-Lavialle; Christian Pagnoux; Nicolas Martin Silva; Amédée Renand; Françoise Galateau-Salle; Sophie Le Toquin; Henri Bensadoun; Frederique Larousserie; Stéphane Silvera; Nicole Provost; Sophie Candon; Raphaèle Seror; Mathilde de Menthon; Olivier Hermine; Loïc Guillevin; Boris Bienvenu
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

3.  Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.

Authors:  Helmut Gadner; Nicole Grois; Ulrike Pötschger; Milen Minkov; Maurizio Aricò; Jorge Braier; Valerie Broadbent; Jean Donadieu; Jan-Inge Henter; Robert McCarter; Stephan Ladisch
Journal:  Blood       Date:  2007-12-18       Impact factor: 22.113

4.  Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.

Authors:  Julien Haroche; Zahir Amoura; Frédéric Charlotte; Juan Salvatierra; Bertrand Wechsler; Carlos Graux; Nicole Brousse; Jean-Charles Piette
Journal:  Blood       Date:  2008-06-01       Impact factor: 22.113

5.  CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Authors:  Laurent Arnaud; Baptiste Hervier; Antoine Néel; Mohamed A Hamidou; Jean-Emmanuel Kahn; Bertrand Wechsler; Gemma Pérez-Pastor; Bjørn Blomberg; Jean-Gabriel Fuzibet; François Dubourguet; António Marinho; Catherine Magnette; Violaine Noel; Michel Pavic; Jochen Casper; Anne-Bérangère Beucher; Nathalie Costedoat-Chalumeau; Laurent Aaron; Juan Salvatierra; Carlos Graux; Patrice Cacoub; Véronique Delcey; Claudia Dechant; Pascal Bindi; Christiane Herbaut; Giorgio Graziani; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

Review 7.  Langerhans cell histiocytosis: Current concepts and treatments.

Authors:  Oussama Abla; R Maarten Egeler; Sheila Weitzman
Journal:  Cancer Treat Rev       Date:  2010-02-25       Impact factor: 12.111

Review 8.  Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases.

Authors:  Stacy L Pineles; Grant T Liu; Xenia Acebes; Jorge Arruga; Sunita Nasta; Ruchira Glaser; Michelle Pramick; Franz Fogt; Peter Le Roux; Roberta E Gausas
Journal:  J Neuroophthalmol       Date:  2011-09       Impact factor: 3.042

Review 9.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

10.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113
View more
  4 in total

1.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

2.  Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Authors:  David M Hyman; Eli L Diamond; Cecile Rose T Vibat; Latifa Hassaine; Jason C Poole; Minal Patel; Veronica R Holley; Goran Cabrilo; Timothy T Lu; Maria E Arcila; Young Rock Chung; Raajit Rampal; Mario E Lacouture; Neal Rosen; Funda Meric-Bernstam; José Baselga; Razelle Kurzrock; Mark G Erlander; Filip Janku; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2014-10-16       Impact factor: 39.397

Review 3.  Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.

Authors:  Anagha Deshpande; Javier Munoz
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

4.  BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.

Authors:  Filip Janku; Cecile Rose T Vibat; Karena Kosco; Veronica R Holley; Goran Cabrilo; Funda Meric-Bernstam; Vanda M Stepanek; Patrick P Lin; Lorieta Leppin; Latifa Hassaine; Jason C Poole; Razelle Kurzrock; Mark G Erlander
Journal:  Oncotarget       Date:  2014-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.